SUBSCRIBE
SUBSCRIBE
News   Drug Development

Inspire Pharmaceuticals, Inc. Initiates Phase 2 14-Day Clinical Trial Of Epinastine For Seasonal Allergic Rhinitis

December 5, 2006 | 
1 min read
DURHAM, N.C.--(BUSINESS WIRE)--Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today the initiation of a Phase 2 clinical trial to evaluate epinastine nasal spray for the treatment of seasonal allergic rhinitis.
Clinical research Phase 2
MORE ON THIS TOPIC
Fashionable halftones collage. Startup business concept,fast business startup. Trendy modern retro illustration in bright trendy colors. Strategic planning concept and business success. Vector illustration
Rare diseases
BridgeBio Builds Case for Early 2027 Launch of Dystrophy Drug
March 12, 2026
 · 
2 min read
 · 
Tristan Manalac
Vertical collage image of black white effect arm hold tied arrow shoot down darts board target isolated on painted background.
Clinical research
MDA 2026: Biogen, Sarepta, Edgewise Address Muscle Disorders
March 12, 2026
 · 
3 min read
 · 
Tristan Manalac
Insights
From Two Trials to One, Sponsors Face a Higher Standard
March 12, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Businessman holding a dart aiming at the target - business targeting, aiming, focus concept. Art collage.
Duchenne muscular dystrophy
Dyne Plans Post-Prasad FDA Run as Duchenne Exon Skipper Sustains Benefit in Long Term Data
March 10, 2026
 · 
3 min read
 · 
Tristan Manalac